MALCOLM BRENNER to Glioma
This is a "connection" page, showing publications MALCOLM BRENNER has written about Glioma.
Connection Strength
0.159
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.086
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.027
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.020
-
Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res. 1998 Oct 15; 58(20):4577-80.
Score: 0.018
-
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci. 1999; 65(5):483-91.
Score: 0.005
-
A downstream initiation element required for efficient TATA box binding and in vitro function of TFIID. Nature. 1990 Nov 01; 348(6296):86-8.
Score: 0.003